Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema (TYBEE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03126786
Recruitment Status : Completed
First Posted : April 24, 2017
Results First Posted : May 13, 2021
Last Update Posted : May 13, 2021
Sponsor:
Information provided by (Responsible Party):
Clearside Biomedical, Inc.

Brief Summary:
The purpose of this trial is to evaluate the safety and efficacy of suprachoroidal CLS-TA used with intravitreal aflibercept in subjects with DME.

Condition or disease Intervention/treatment Phase
Diabetic Macular Edema Drug: IVT aflibercept Drug: Sham SC Drug: SC CLS-TA Phase 2

Detailed Description:

This is a Phase 2, multicenter, randomized, double-masked, controlled, parallel-group study of 6 months duration in treatment-naïve subjects with DME. This study is projected to enroll approximately 60 subjects, randomly assigned 1:1 to one of two treatment groups.

The study design includes up to 8 clinic visits over approximately 24 weeks. Subjects will attend visits for Screening (Visit 1, Days -30 to 0); Randomization and Baseline (Visit 2, Day 0 before dosing); Dosing and Evaluation (Visit 2 after dosing to Visit 5, Day 0 through Week 12); As-needed (PRN) Dosing and Follow up (Visit 6 through Visit 7, Week 16 through Week 20), and End of Study (Visit 8, Week 24).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
Actual Study Start Date : July 11, 2017
Actual Primary Completion Date : April 17, 2018
Actual Study Completion Date : April 17, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arm Intervention/treatment
Active Comparator: Active
Treatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
Drug: IVT aflibercept
IVT aflibercept [2 mg/0.05 mL]
Other Name: Eylea

Drug: SC CLS-TA
CLS-TA [4 mg/100 μL] SC injection
Other Name: Triamcinolone Acetonide

Sham Comparator: Control
Treatment will consist of IVT aflibercept injection followed by a sham SC procedure
Drug: IVT aflibercept
IVT aflibercept [2 mg/0.05 mL]
Other Name: Eylea

Drug: Sham SC
sham SC
Other Name: suprachoroidal sham




Primary Outcome Measures :
  1. Mean Change From Baseline in Best Corrected Visual Acuity Letter Score [ Time Frame: Baseline, 6 months ]
    Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.


Secondary Outcome Measures :
  1. Mean Change From Baseline in Central Subfield Thickness [ Time Frame: Baseline, 6 months ]
    Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of type 1 or type 2 DM
  • DME with central involvement (> 300 µm in the central subfield on spectral-domain optical coherence tomography [SD-OCT], in the study eye
  • ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye
  • Naïve to local pharmacologic treatment for DME in the study eye

Exclusion Criteria:

  • IOP > 21 mmHg in the study eye at Visit 1 (Day -30 to -1); subjects are not excluded if IOP is <22 mmHg in the study eye with no more than 1 IOP lowering medication
  • Any previous treatment in the study eye with an ocular corticosteroid implant
  • Has significant media opacity precluding evaluation of retina and vitreous in the study eye.
  • History of glaucoma or optic nerve head change consistent with glaucoma damage
  • History of glaucoma surgery
  • History of clinically significant IOP elevation in response to corticosteroid treatment ("steroid responder")

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03126786


Locations
Show Show 29 study locations
Sponsors and Collaborators
Clearside Biomedical, Inc.
Investigators
Layout table for investigator information
Study Director: Thomas Ciulla, MD Clearside Biomedical
  Study Documents (Full-Text)

Documents provided by Clearside Biomedical, Inc.:
Layout table for additonal information
Responsible Party: Clearside Biomedical, Inc.
ClinicalTrials.gov Identifier: NCT03126786    
Other Study ID Numbers: CLS1004-201
First Posted: April 24, 2017    Key Record Dates
Results First Posted: May 13, 2021
Last Update Posted: May 13, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Clearside Biomedical, Inc.:
Diabetes Mellitus
Diabetic Retinopathy
Microneedle
Mircoinjection
Triamcinolone
Choroid
Choroid Injection
Aflibercept
Suprachoroidal
Triamcinolone acetonide
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Edema
Edema
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Triamcinolone
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action